GLP-1s

GLP-1 drugs may slightly raise the risk of osteoporosis, according to a pair of new studies. In one study, presented March 2 at the American Academy of Orthopaedic Surgeons’ annual meeting, researchers evaluated five years of medical records from more…

Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is eligible to receive up to…

Walgreens has expanded its virtual care platform to include weight management services, offering $49 clinician-guided visits for eligible adults using GLP-1 therapies. The new Walgreens Weight Management program is open to self-pay patients ages 18-64 who are overweight or have…

Novo Nordisk will reduce the U.S. list price of Wegovy, Ozempic and Rybelsus to $675 per month starting Jan. 1, 2027. The change constitutes a list price reduction of approximately 50% for Wegovy and 35% for Ozempic across all doses,…

A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss. The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema…

Eli Lilly has launched a multidose version of its blockbuster weight loss drug Zepbound that gives patients a month’s worth of treatment in a single injection pen.   On Feb. 23, the drugmaker said the FDA approved a label expansion for…

Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or overweight. At 36 weeks, 27.1% of patients receiving both drugs…

In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of chronic kidney disease and acute kidney injury.  The study, published Jan. 20 in JAMA, analyzed the comparative effectiveness of both…

Telehealth company eMed has partnered with CVS Caremark to offer a GLP-1 benefit model that lets employers subsidize weight loss medications without covering the full cost, Axios reported Feb. 16.  The arrangement allows eligible employees to purchase GLP-1s online through…

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. Here are three trends driving the drug class forward: 1. Regulatory momentum accelerates On Jan. 13, the FDA directed…